Kolodziejczyk P, Pituch-Noworolska A, Drabik G, Kulig J, Szczepanik A, Sierzega M, Gurda A, Popiela T, Zembala M
1st Department of Surgery, Jagiellonian University Medical College, 40 Kopernika Street, Krakow 31-501, Poland.
Br J Cancer. 2007 Sep 3;97(5):589-92. doi: 10.1038/sj.bjc.6603904. Epub 2007 Aug 14.
Recent studies in breast cancer suggest that monitoring the isolated tumour cells (ITC) may be used as a surrogate marker to evaluate the efficacy of systemic chemotherapy. In the present study, we have investigated the effects of preoperative chemotherapy on ITC in the blood and bone marrow of patients with potentially resectable gastric cancer. After sorting out the CD45-positive cells, the presence of ITC defined as cytokeratin-positive cells was examined before and after preoperative chemotherapy. The patients received two courses of preoperative chemotherapy with cisplatin (100 mg m(-2), day 1) and 5-fluorouracil (1000 mg m(-2), days 1-5), administered every 28 days. Fourteen of 32 (44%) patients initially diagnosed with ITC in blood and/or bone marrow were found to be negative (responders) after preoperative chemotherapy (P<0.01). The incidence of ITC in bone marrow was also significantly (P<0.01) reduced from 97 (31 of 32) to 53% (17 of 32). The difference between patients positive for ITC in the blood before (n=7, 22%) and after (n=5, 16%) chemotherapy was statistically insignificant. The overall 3-year survival rates were 32 and 49% in the responders and non-responders, respectively (P=0.683). These data indicate that preoperative chemotherapy can reduce the incidence of ITC in patients with gastric cancer.
近期乳腺癌研究表明,监测循环肿瘤细胞(ITC)可用作评估全身化疗疗效的替代标志物。在本研究中,我们调查了术前化疗对潜在可切除胃癌患者血液和骨髓中ITC的影响。分选CD45阳性细胞后,在术前化疗前后检查定义为细胞角蛋白阳性细胞的ITC的存在情况。患者接受两疗程术前化疗,顺铂(100 mg m(-2),第1天)和5-氟尿嘧啶(1000 mg m(-2),第1 - 5天),每28天给药一次。32例最初在血液和/或骨髓中诊断为ITC的患者中,14例(44%)在术前化疗后变为阴性(反应者)(P<0.01)。骨髓中ITC的发生率也显著(P<0.01)从97%(32例中的31例)降至53%(32例中的17例)。化疗前血液中ITC阳性患者(n = 7,22%)和化疗后(n = 5,16%)之间的差异无统计学意义。反应者和无反应者的总体3年生存率分别为32%和49%(P = 0.683)。这些数据表明术前化疗可降低胃癌患者ITC的发生率。